Solid Biosciences Reports Efficacy and Safety Data from Duchenne Trial

  Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function tests (PFTs), and clinically validated patient reported outcome measures (PROMs) -

- Patient 7, safely dosed with SGT-001, experienced transient and manageable adverse events, none of which were serious; six patients previously dosed showed no new drug-related safety findings 17-37 months post dosing; screening and enrollment of patients into IGNITE DMD continue -

- Presentations to follow at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference -

- Company to host conference call and webcast today at 4:30 PM ET to discuss clinical data and financial results -

Conference Call Today at 4:30 PM ET
Management will host a webcast and conference call to review the IGNITE DMD data and will take questions on this data and Solid’s financial results, today at 4:30 PM ET.

A live webcast of the call will be available on the Company's website at www.solidbio.com under the “News & Events” tab in the Investor Relations section, or by clicking here. Participants may also access the call, by dialing 866-763-0341 for domestic callers or 703-871-3818 for international callers, referencing conference ID# 1669808.

The archived webcast will be available for in the “News and Events” section of the Company's website.

https://www.globenewswire.com/news-release/2021/03/15/2193181/0/en/Solid-Biosciences-Reports-Efficacy-and-Safety-Data-from-the-Ongoing-IGNITE-DMD-Clinical-Trial-and-Resumption-of-Patient-Dosing-in-the-2E14-vg-kg-Cohort.html